

**FANCONI CANADA**

Unaudited Financial Statements

December 31<sup>st</sup>, 2012

Prepared By:

Annette Waxberg  
Treasurer

June 30, 2013

**FANCONI CANADA****Statement of Financial Position**  
(Unaudited)

As at December 31, 2012

	<u>Dec. 31, 2012</u>	<u>Dec. 31, 2011</u>
<b>CURRENT ASSETS</b>		
Bank accounts	\$27,538	\$43,066
GIC and other current assets	337,201	333,861
<b>TOTAL CURRENT ASSETS</b>	<u>\$364,739</u>	<u>\$376,928</u>
<b>LIABILITIES &amp; NET ASSETS</b>		
Payables	\$85	\$6,000
Net Assets internally restricted for research (note 3)	321,335	328,601
Unrestricted net assets	43,319	42,327
<b>TOTAL LIABILITIES &amp; NET ASSETS</b>	<u>\$364,739</u>	<u>\$376,928</u>

June 30, 2013

**FANCONI CANADA****Statement of Operations**  
(Unaudited)

For the year ended December 31, 2012

	Jan. 1, 2011 to <u>Dec. 31, 2012</u>	Jan. 1, 2011 to <u>Dec. 31, 2011</u>
<b>REVENUES</b>		
Research contributions	\$148,666	\$140,977
Unrestricted contributions	45	873
Interest income	3,937	7,840
Total revenues	<u>\$152,648</u>	<u>\$149,690</u>
<b>GRANTS &amp; EXPENSES</b>		
Research projects funded (notes 4 to 10)	\$120,586	\$116,354
Direct Fundraising expenses	35,346	32,235
Administrative expenses	2,990	2,487
Total grants & expenses	<u>\$158,922</u>	<u>\$151,076</u>
<b>Excess &lt;deficit&gt; of revenues over grants &amp; expenses</b>	<u>&lt;\$6,274&gt;</u>	<u>&lt;\$1,386&gt;</u>

June 30, 2013

**FANCONI CANADA****Statement of Changes in Net Assets**  
(Unaudited)

As at Dec. 31, 2012

	<u>Internally Restricted for Research</u>	<u>Unrestricted</u>	<u>Dec. 31, 2012</u>	<u>Dec. 31, 2011</u>
<b>NET ASSETS</b>				
Balance, beginning of year	\$328,601	\$42,327	\$370,928	\$372,314
Excess <deficit> of revenues over expenses, research	<7,266>		<7,266>	<7,612>
Excess <deficit> of expenses over revenues, administration		992	992	6,226
<b>BALANCE, END OF YEAR</b>	<u>\$321,335</u>	<u>\$43,319</u>	<u>\$364,654</u>	<u>\$370,928</u>

June 30, 2013

**FANCONI CANADA****Statement of Cash Flows**  
(Unaudited)

For the year ended December 31, 2012

	<u>Jan. 1, 2012 to</u> <u>Dec. 31, 2012</u>	<u>Jan. 1, 2011 to</u> <u>Dec. 31, 2011</u>
<b>Cash flows from operating activities</b>		
Net fundraising for research (note 4):		
Ontario Fundraiser	\$75,843	\$76,743
Scotiabank Waterfront Run	20,598	17,046
General Donations	1,527	1,620
LAWPRO Employee Fundraising	5,223	5,277
Lauzier Family Fundraiser	7,222	5,500
Kestenberg Siegel Lipkus Casual Days	2,090	2,242
Tribute Cards	538	25
	<hr/>	<hr/>
	113,041	108,453
Administrative contributions	45	873
Interest	3,937	7,840
Research projects:		
Vignard (note 5)	-	<10,000>
Jones (note 6)	<1,667>	<22,500>
Mistry (note 7)	-	<875>
Larin (note 8)	<11,000>	<11,000>
Kaddar (note 9)	<22,500>	<22,500>
St-Laurent Pedneault (note 10)	-	<3,646>
Kwan (note 11)	<22,500>	<20,833>
Tarailo-Graovac (note 12)	<16,875>	<22,500>
Carreau (note 13)	<46,044>	-
Other research projects	-	<2,500>
Administrative costs	<2,711>	<2,198>
Net increase <decrease> in payables	<3,510>	1,822
<b>Net cash generated through operating activities</b>	<hr/>	<hr/>
	<9,784>	436
<b>Cash flows from financing &amp; investing activities</b>	-	-
Cash & GIC's, beginning of year	374,523	374,087
<b>Cash &amp; GIC's, end of year</b>	<hr/>	<hr/>
	364,739	374,523

**FANCONI CANADA****Notes to Financial Statements**  
(Unaudited)

As at December 31, 2012

**1. Purpose of the Organization**

Fanconi Canada (Canadian Fanconi Anemia Research Fund/La Fondation Canadienne de Recherche de L'Anemie de Fanconi) raises money to fund research on finding a cure and/or treatment for Fanconi Anemia (a fatal genetic disease causing bone marrow failure and physical anomalies); to raise awareness among members of the general public and the medical community about Fanconi Anemia, its diagnosis and methods of treatment; to provide support to Canadian families affected by Fanconi Anemia; and the publication of newsletters and educational materials in furtherance of the foregoing objectives. Fanconi Canada is incorporated under the Canada Corporations Act as a not-for-profit organization and is a registered charity under the Income Tax Act.

**2. Significant Accounting Policies****Revenue recognition**

Fanconi Canada follows the deferral method of accounting for contributions. Restricted contributions are recognized as revenue in the year in which the related expenses are incurred. Unrestricted contributions are recognized as revenue when received or receivable if the amount to be received can be reasonably estimated and collection is reasonably assured. Unrestricted investment income is recognized as revenue when earned.

**Investments**

Investments are recorded at the lower of cost and market value.

**Contributed services**

Volunteers contribute many hours per year to assist Fanconi Canada in carrying out its service delivery activities, fundraising and day-to-day operations. Because of the difficulty of determining their fair value, contributed services are not recognized in the financial statements.

### **3. Restrictions on net assets**

Fanconi Canada has no net assets with externally imposed restrictions; however, donations from the public are internally restricted to be used for research. Some donations from families afflicted with Fanconi Anemia are directed to cover Fanconi Canada services and administrative expenses, which are also covered by interest revenue.

### **4. Raffles at Ontario Fundraisers 2011 and 2012**

Fanconi Canada ran 50/50 draws at both the 2011 Ontario Fundraiser and the 2012 Ontario Fundraiser, which required a Lottery Licence from the City of Toronto. The licence for 2011 was issued April 13, 2011 and numbered M660458 and the licence for 2012 was issued March 30, 2012 and numbered M698342. The licences impose restrictions on the use of lottery proceeds in that they must benefit Toronto residents. Therefore, all the proceeds from both raffles were used to fund the research performed at the University of Toronto by Meghan E. Larin (see note 8 below) in each of 2011 and 2012.

### **5. Contractual Obligations – Julien Vignard**

A Post-Doctoral Fellowship in FA Research in partnership with CIHR for the 2007 Competition was awarded to Julien Vignard of Laval University in Quebec City for his project studying the role of FA proteins in DNA double-stranded break repair. Fanconi Canada's obligation is for one half of \$45,000 per year for three years commencing April 2008. Subsequently, he postponed his CIHR funding to the period May 1, 2009 to April 30, 2012. Finally, his funding will be terminated early on August 15, 2011, due to his return to France.

### **6. Contractual Obligations – Dr. Martin R. Jones**

The Canadian Institutes of Health Research/Fanconi Canada Post-Doctoral Fellowship in FA Research (under the 2008 CIHR Small Health Organization Partnership Program) was awarded to Dr. Martin R. Jones of the University of British Columbia. Dr. Jones' project is titled *Characterization of Fanconi anemia and a FA genetic network in C. elegans: A model for developing Fanconi Anemia therapeutic targets*. This three year fellowship has a value of \$135,000 which will be funded equally by CIHR and Fanconi Canada from May 1, 2009 to April 30, 2012.

### **7. Contractual Obligations – Helena S. Mistry**

Helena S. Mistry of the Hospital for Sick Children in Toronto received the Canadian Institutes of Health Research/Fanconi Canada Doctoral Research Award in FA Research (under the 2008 CIHR Small Health Organization Partnership Program). Dr. Mistry's project is titled *Relationship of Mus81-Eme1 to Fanconi Anemia signaling I the DNA damage response*. This two year fellowship has a value of \$44,000 which will be funded equally by CIHR and Fanconi Canada from May 1, 2009 to April 30, 2011.

### **8. Contractual Obligations – Meghan E. Larin**

Fanconi Canada in partnership with the Canadian Institutes of Health Research, has agreed to fund (under the 2009 CIHR Small Health Organization Partnership Program), a three-year doctoral research award to Meghan E. Larin of the University of Toronto, Department of Pharmacology and Toxicology for her project entitled *Fanconi Anemia signaling and Mus81-Eme1: role in replicative stress and development*. The award is for \$22,000 per year for a total of \$66,000 funded equally by Fanconi Canada and CIHR from September 1, 2010 to August 31, 2013.

### **9. Contractual Obligations – Tagrid Kaddar**

Fanconi Canada in partnership with the Canadian Institutes of Health Research (under the 2009 CIHR Small Health Organization Partnership Program), has granted a three-year Fellowship Award to Tagrid Kaddar of Université Laval, Québec to study the role of Fanconi proteins in hematopoiesis. The award is for \$45,000 per year for a total of \$135,000 funded equally by Fanconi Canada and CIHR from September 1, 2010 to August 31, 2013.

### **10. Contractual Obligations – Christopher W. St-Laurent Pedneault**

Fanconi Canada in partnership with the Canadian Institutes of Health Research (under the 2010 CIHR Small Health Organization Partnership Program), has granted a one year Master's Award to Christopher St-Laurent Peneault of Université Laval, Québec to study functional splice variants in FANCA cells and their effects on DNA repair. The award is for \$17,500, funded equally by Fanconi Canada and CIHR from September 1, 2010 to August 31, 2011.



### **11. Contractual Obligations – David Howe Kwan**

Fanconi Canada in partnership with the Canadian Institutes of Health Research (under the 2010 CIHR Small Health Organization Partnership Program), has granted a three-year Fellowship Award to David Howe Kwan of the University of British Columbia for his project *Improving Enzymatic Removal of Major Blood Antigens* to help improve the availability and safety of blood transfusions. The award is for \$45,000 per year for a total of \$135,000 funded equally by Fanconi Canada and CIHR from May 1, 2011 to April 30, 2014.

### **12. Contractual Obligations – Maja Tarailo-Graovac**

Fanconi Canada in partnership with the Canadian Institutes of Health Research (under the 2010 CIHR Small Health Organization Partnership Program), has granted a two year Fellowship Award to Maja Tarailo-Graovac of Simon Fraser University for the project *Genome Variations that Drive Increased Fitness in MAD1 and FANCC-J-Defective C. elegans* which could add to the knowledge regarding the cause of Fanconi anemia as well as causation and development of cancer in general. The award was originally announced for \$78,750, funded equally by Fanconi Canada and CIHR from April 1, 2011 to Dec. 31, 2012. Subsequently, due to a request for maternity leave, the project end date was extended to November 30, 2013 with the funding increased to \$95,417, the difference of \$16,667 being fully funded by CIHR.

### **13. Contractual Obligations – Dr. Madeleine Carreau**

In 2011, Fanconi Canada in partnership with the Fanconi Anemia Research Fund (FARF) of Eugene Oregon agreed to fund the project *Exploring the role of FANCC in developmental cell death*, carried out by Dr. Madeleine Carreau of Laval University, Quebec City, Quebec. The project was to run from January 1, 2012 to December 31, 2013 requiring \$189,192 in total, to be funded equally by Fanconi Canada and FARF. Subsequently, the project length was shortened by Dr. Carreau to one year with half the amount required for funding. On November 12, 2012 Fanconi Canada agreed to send \$94,596, thereby funding the full amount of the research in two installments, half in 2012 and the other half in 2013.

#### **14. Contractual Obligations – Dr. Jeffrey S. Chu**

Fanconi Canada in partnership with the Canadian Institutes of Health Research (under the 2012 CIHR Small Health Organization Partnership Program), has granted a three-year Fellowship Award to Jeffrey S. Chu of the University of British Columbia for his project *Characterization of genomic alteration in C. elegans lacking Fanconi anemia pathway function* to better understand the FA pathway. The award is for \$45,000 per year for a total of \$135,000 funded equally by Fanconi Canada and CIHR from May 1, 2013 to July 1, 2016.

#### **15. Contractual Obligations – Abigail Mateo**

Fanconi Canada in partnership with the Canadian Institutes of Health Research (under the 2012 CIHR Small Health Organization Partnership Program), has granted a three-year Doctoral Research Award to Abigail Mateo of the Hospital for Sick Children, Toronto for her project *C. elegans p53 family transcription factor has roles in meiotic recombination and DNA interstrand crosslink* to better understand DNA repair with respect to the FA pathway. The award is for \$35,000 per year for a total of \$105,000 funded equally by Fanconi Canada and CIHR from May 1, 2013 to April 30, 2016.

## 15. Ontario Fundraiser

The following is a breakdown of the Annual Ontario Fundraiser, the major fundraising initiative for Fanconi Canada.

### Ontario Fundraiser Amount Raised for Research (Unaudited)

For the year ended December 31, 2012

	<u>2012 Fundraiser</u>	<u>2011 Fundraiser</u>
<b>REVENUES</b>		
Table sponsorships	\$65,420	\$50,900
Auction items	19,794	22,550
Donations	13,568	22,178
Ticket sales	10,465	8,795
Raffle tickets	633	3,600
Event novelties	-	440
Total revenues	<u>\$109,880</u>	<u>\$108,463</u>
<b>DIRECT FUNDRAISING EXPENSES</b>	<u>&lt;34,049&gt;</u>	<u>&lt;32,745&gt;</u>
<b>Amount raised for research</b>	<u>\$75,831</u>	<u>\$75,718</u>

## 16. Scotiabank Waterfront Marathon

In 2010, Fanconi Canada has undertaken a new fundraising event by entering a team in the Scotiabank Waterfront Marathon. The following details the success of the event.

### Scotiabank Waterfront Marathon Amount Raised for Research (Unaudited)

For the year ended December 31, 2012

	<u>2012</u>	<u>2011</u>
<b>REVENUES</b>		
Team and Individual Runner Sponsorships	\$22,138	\$17,837
<b>DIRECT FUNDRAISING EXPENSES</b>	<u>&lt;1,540&gt;</u>	<u>&lt;791&gt;</u>
<b>Amount raised for research</b>	<u>\$20,598</u>	<u>\$17,046</u>